Go or no go? Bristol’s Lag3 debut

A green light is expected for Bristol’s anti-Lag3 relatlimab next month given its impressive PFS data. The antibody is administered as a fixed dose combination with Opdivo and the phase 2/3 study Relativity-047 in unresectable or metastatic melanoma showed a median PFS of 10.1 months versus 4.6 months for Opdivo alone.